Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

BASF, Cargill and Novozymes Achieve Milestone in Bio-Based Acrylic Acid Process

Published: Thursday, July 11, 2013
Last Updated: Thursday, July 11, 2013
Bookmark and Share
Success in producing 3-hydroxypropionic acid for bio-based acrylic acid.

BASF, Cargill and Novozymes have announced the achievement of an important milestone in their joint development of technologies to produce acrylic acid from renewable raw materials by successfully demonstrating the production of 3-hydroxypropionic acid (3-HP) in pilot scale.

3-HP is a renewable-based building block and one possible chemical precursor to acrylic acid. The companies also have successfully established several technologies to dehydrate 3-HP to acrylic acid at lab scale.

This step in the process is critical since it is the foundation for production of acrylic acid. In August 2012, BASF, Cargill and Novozymes announced their joint agreement to develop a process for the conversion of renewable raw materials into a 100 percent bio-based acrylic acid.

“3-HP is a potential key raw material for the production of bio-based acrylic acid which is a precursor of superabsorbent polymers,” said Teressa Szelest, Senior Vice President Global Hygiene Business at BASF.

Szelest continued, “We still have a fair amount of work to do before the process is commercially ready, but this is a significant milestone and we are confident we can continue to the next level of scale-up for the entire process in 2014.”

Acrylic acid is a high-volume chemical that feeds into a broad range of products. BASF is the world’s largest producer of acrylic acid and has substantial capabilities in its production and downstream processing.

BASF plans initially to use the bio-based acrylic acid to manufacture superabsorbent polymers that can soak up large amounts of liquid and are used mainly in baby diapers and other hygiene products.

Presently, acrylic acid is produced by the oxidation of propylene derived from the refining of crude oil.

The companies’ joint project team combines world-class expertise in biotechnology, renewable feedstock, industrial scale fermentation, and in developing new chemical processes.

“Our three companies have assembled highly talented and experienced joint working teams for this project,” said Jack Staloch, Vice President of Biotechnology R&D at Cargill.

Staloch continued, “They’ve moved with speed and intensity, and have demonstrated great progress toward accomplishing our goals.”

“We have reached an important milestone by producing 3-HP in pilot scale,” said Rasmus von Gottberg, Vice President of Corporate Development and Business Creation at Novozymes. “We have shown that it is possible to make this key chemical building block from renewable raw materials in robust industrial conditions. Now the development work will continue towards commercialization.”

Superabsorbent polymers derived from bio-based acrylic acid will be a groundbreaking new offer to the market. Diapers made of such superabsorbent polymers could meet the demand of a significant and growing group of consumers in mature markets in particular.

They also may allow diaper producers to meet consumer demands, differentiate their products and contribute to their sustainability goals.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novozymes Biopharma Helps Innovative Dry Eye Therapy Move into Clinical Trials
A novel ophthalmic solution has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States.
Monday, May 20, 2013
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos